Evaluation of 64Cu Labeled GX1: A Phage Display Peptide Probe for PET Imaging of Tumor Vasculature

详细信息    查看全文

• 作者：Kai Chen (1) (2)
  Xilin Sun (2)
  Gang Niu (2)
  Ying Ma (2)
  Li-Peng Yap (1)
  Xiaoli Hui (3)
  Kaichun Wu (3)
  Daiming Fan (3)
  Peter S. Conti (1)
  Xiaoyuan Chen (2)
  
• 关键词：64Cu ; Labeled GX1 peptide ; PET imaging ; Tumor vasculature ; Phage display
• 刊名：Molecular Imaging and Biology
• 出版年：2012
• 出版时间：February 2012
• 年：2012
• 卷：14
• 期：1
• 页码：96-105
• 全文大小：378KB
• 参考文献：1. Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219:316-33
  2. Chen K, Chen X (2010) Design and development of molecular imaging probes. Curr Top Med Chem 10:1227-236 CrossRef
  3. Massoud TF, Gambhir SS (2003) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545-80 CrossRef
  4. Chen K, Conti PS (2010) Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 62:1005-022 CrossRef
  5. Deutscher SL (2010) Phage display in molecular imaging and diagnosis of cancer. Chem Rev 110:3196-211 CrossRef
  6. Chen B, Cao S, Zhang Y, Wang X, Liu J, Hui X, Wan Y, Du W, Wang L, Wu K, Fan D (2009) A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol 10:63 CrossRef
  7. Zhi M, Wu KC, Dong L, Hao ZM, Deng TZ, Hong L, Liang SH, Zhao PT, Qiao TD, Wang Y, Xu X, Fan DM (2004) Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancer. Cancer Biol Ther 3:1232-235 CrossRef
  8. Hui X, Han Y, Liang S, Liu Z, Liu J, Hong L, Zhao L, He L, Cao S, Chen B, Yan K, Jin B, Chai N, Wang J, Wu K, Fan D (2008) Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release 131:86-3 CrossRef
  9. Cai W, Gambhir SS, Chen X (2008) Chapter 7. Molecular imaging of tumor vasculature. Methods Enzymol 445:141-76 CrossRef
  10. Weissleder R (2006) Molecular imaging in cancer. Science 312:1168-171 CrossRef
  11. Weissleder R (2002) Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer 2:11-8 CrossRef
  12. Cai W, Rao J, Gambhir SS, Chen X (2006) How molecular imaging is speeding up antiangiogenic drug development. Mol Cancer Ther 5:2624-633 CrossRef
  13. Blower PJ, Lewis JS, Zweit J (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23:957-80 CrossRef
  14. Liu S (2008) Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides. Adv Drug Deliv Rev 60:1347-370 CrossRef
  15. Sun X, Anderson CJ (2004) Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol 386:237-61 CrossRef
  16. Anderson CJ, Ferdani R (2009) Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 24:379-93 CrossRef
  17. Shokeen M, Anderson CJ (2009) Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 42:832-41 CrossRef
  18. Liu Z, Niu G, Wang F, Chen X (2009) (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 36:1483-494 CrossRef
  19. Sun X, Niu G, Yan Y, Yang M, Chen K, Ma Y, Chan N, Shen B, Chen X (2010) Phage display-derived peptides for osteosarcoma imaging. Clin Cancer Res 16:4268-277 CrossRef
  20. Chen K, Chen X (2011) PET Imaging of cancer biology: current status and future prospects. Semin Oncol 38:70-6 CrossRef
  21. Ellis LM, Liu W, Ahmad SA, Fan F, Jung YD, Shaheen RM, Reinmuth N (2001) Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin Oncol 28:94-04 CrossRef
  22. Kuwano M, Fukushi J, Okamoto M, Nishie A, Goto H, Ishibashi T, Ono M (2001) Angiogenesis factors. Intern Med 40:565-72 CrossRef
  23. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242-48 CrossRef
  24. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-10 CrossRef
  25. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-64 CrossRef
  26. Ueberberg S, Schneider S (2010) Phage library-screening: a powerful approach for generation of targeting-agents specific for normal pancreatic islet-cells and islet-cell carcinoma / in vivo. Regul Pept 160:1- CrossRef
  27. Soda Y, Marumoto T, Friedmann-Morvinski D, Soda M, Liu F, Michiue H, Pastorino S, Yang M, Hoffman RM, Kesari S, Verma IM (2011) Feature article: transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A (in press)
  28. Chen X, Park R, Hou Y, Tohme M, Shahinian AH, Bading JR, Conti PS (2004) microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 45:1390-397
  29. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, Liu S, Gambhir SS, Chen X (2005) microPET imaging of glioma integrin {alpha}v{beta}3 expression using (64)Cu-labeled tetrameric RGD peptide. J Nucl Med 46:1707-718
  30. Li ZB, Cai W, Cao Q, Chen K, Wu Z, He L, Chen X (2007) (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression. J Nucl Med 48:1162-171 CrossRef
  31. Cai W, Wu Y, Chen K, Cao Q, Tice DA, Chen X (2006) / In vitro and / in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cancer Res 66:9673-681 CrossRef
  32. Chen X, Liu S, Hou Y, Tohme M, Park R, Bading JR, Conti PS (2004) MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6:350-59 CrossRef
  33. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, Anderson CJ (2004) Comparative / in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47:1465-474 CrossRef
  34. Sun X, Wuest M, Weisman GR, Wong EH, Reed DP, Boswell CA, Motekaitis R, Martell AE, Welch MJ, Anderson CJ (2002) Radiolabeling and / in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 45:469-77 CrossRef
  35. Cai H, Li Z, Huang CW, Shahinian AH, Wang H, Park R, Conti PS (2010) Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved MicroPET imaging of integrin alphavbeta3 expression. Bioconjug Chem 21:1417-424 CrossRef
  36. Cai H, Li Z, Huang CW, Park R, Shahinian AH, Conti PS (2010) An improved synthesis and biological evaluation of a new cage-like bifunctional chelator, 4-((8-amino-3, 6, 10, 13, 16, 19-hexaazabicyclo[6.6.6]icosane-1-ylamino)methyl)benzoic acid, for 64Cu radiopharmaceuticals. Nucl Med Biol 37:57-5 CrossRef
  37. Chen X (2006) Multimodality imaging of tumor integrin alphavbeta3 expression. Mini Rev Med Chem 6:227-34 CrossRef
  38. Haubner R, Wester HJ, Weber WA, Mang C, Ziegler SI, Goodman SL, Senekowitsch-Schmidtke R, Kessler H, Schwaiger M (2001) Noninvasive imaging of alpha(v)beta3 integrin expression using 18?F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 61:1781-785
  39. Shi J, Kim YS, Zhai S, Liu Z, Chen X, Liu S (2009) Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers. Bioconjug Chem 20:750-59 CrossRef
  
• 作者单位：Kai Chen (1) (2)
  Xilin Sun (2)
  Gang Niu (2)
  Ying Ma (2)
  Li-Peng Yap (1)
  Xiaoli Hui (3)
  Kaichun Wu (3)
  Daiming Fan (3)
  Peter S. Conti (1)
  Xiaoyuan Chen (2)
  
  1. Molecular Imaging Center, Department of Radiology, Keck School of Medicine, University of Southern California, 2250 Alcazar Street, CSC 103, Los Angeles, CA, 90033-9061, USA
  2. Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), 31 Center Drive, Suite 1C14, Bethesda, MD, 20892-2281, USA
  3. State Key Laboratory of Cancer Biology & Institute of Digestive Diseases, Xijing Hospital, The Fourth Military Medical University, 710032, Xi’an, Shanxi, China
  

文摘

Purpose Molecular imaging using positron emission tomography (PET) radiotracers targeted to tumor vasculature offers a noninvasive method for early detection of tumor angiogenesis and efficient monitoring of response to anti-tumor vasculature therapy. The previous in vitro results demonstrated that the GX1 peptide, identified by phage display technology, is a tumor vasculature endothelium-specific ligand. In this study, we evaluated a 64Cu-labeled GX1 peptide as a potential radiotracer for microPET imaging of tumor vasculature in a U87MG tumor xenografted mouse model. Methods Macrocyclic chelating agent 1,4,7,10-tetraazacyclododecane-N, N- N′- N′′-tetraacetic acid (DOTA)-conjugated GX1 peptide was synthesized and radiolabeled with 64Cu (t 1/2--2.7?h) in ammonium acetate buffer. The 64Cu-labeled GX1 peptide was then subjected to in vitro tumor cell uptake study, small animal PET and direct tissue sampling biodistribution studies in a U87MG tumor xenografted mouse model. Results The in vitro experiment demonstrated that 64Cu-DOTA-GX1 is stable in PBS with more than 91% of 64Cu-DOTA-GX1 peptide remaining intact after 24?h of incubation. Cellular uptake and retention studies revealed 64Cu-DOTA-GX1 binds to U87MG glioma cells and has good tumor cell retention. For small animal PET imaging studies, the U87MG tumors were all clearly visible with high contrast to contralateral background at all measured time points after injection of 64Cu-DOTA-GX1 while high accumulation in liver and kidneys were also observed at early time points. The U87MG tumor uptake was determined to be the highest (7.97?±-.75%ID/g) at 24?h pi. The blocking experiment was achieved by co-injection of 64Cu-DOTA-GX1 with non-radiolabeled GX1 peptide (20?mg/kg) at 24?h pi, suggesting 64Cu-DOTA-GX1 is a target-specific tracer. Furthermore, the biodistribution results were consistent with the quantification of microPET imaging, demonstrating the highest ratio (16.09?±-.21) of tumor/muscle uptake of 64Cu-DOTA-GX1 at 24?h pi for non-blocking group and significant decreased ratio (6.57?±-.58) for blocking group. Finally, metabolic studies suggested that 64Cu-DOTA-GX1 is stable in mouse blood and urine in vivo at early time point while the metal transchelation may also occur in mouse liver and kidneys. Conclusion Our studies demonstrate that 64Cu-DOTA-GX1 is a promising radiotracer for imaging tumor vasculature.